S&P 500   4,274.04
DOW   33,980.32
QQQ   328.49
Agilent Technologies Proves Its Worth VS Illumina 
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Target’s Results Cap Upside Potential For Retail Stocks 
Wind energy boom and golden eagles collide in the US West
Lowe’s Stands Out Amid Q2 Retail Reports 
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Egypt's central bank governor resigns as economic woes mount
Target takes a hit after heavy discounts to clear inventory
Stocks slip on Wall Street, erasing weekly gains for S&P 500
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
S&P 500   4,274.04
DOW   33,980.32
QQQ   328.49
Agilent Technologies Proves Its Worth VS Illumina 
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Target’s Results Cap Upside Potential For Retail Stocks 
Wind energy boom and golden eagles collide in the US West
Lowe’s Stands Out Amid Q2 Retail Reports 
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Egypt's central bank governor resigns as economic woes mount
Target takes a hit after heavy discounts to clear inventory
Stocks slip on Wall Street, erasing weekly gains for S&P 500
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
S&P 500   4,274.04
DOW   33,980.32
QQQ   328.49
Agilent Technologies Proves Its Worth VS Illumina 
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Target’s Results Cap Upside Potential For Retail Stocks 
Wind energy boom and golden eagles collide in the US West
Lowe’s Stands Out Amid Q2 Retail Reports 
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Egypt's central bank governor resigns as economic woes mount
Target takes a hit after heavy discounts to clear inventory
Stocks slip on Wall Street, erasing weekly gains for S&P 500
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
S&P 500   4,274.04
DOW   33,980.32
QQQ   328.49
Agilent Technologies Proves Its Worth VS Illumina 
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Target’s Results Cap Upside Potential For Retail Stocks 
Wind energy boom and golden eagles collide in the US West
Lowe’s Stands Out Amid Q2 Retail Reports 
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Egypt's central bank governor resigns as economic woes mount
Target takes a hit after heavy discounts to clear inventory
Stocks slip on Wall Street, erasing weekly gains for S&P 500
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
NASDAQ:BLFS

BioLife Solutions - BLFS Stock Forecast, Price & News

$22.73
-2.62 (-10.34%)
(As of 08/17/2022 12:00 AM ET)
Add
Compare
Today's Range
$22.59
$25.84
50-Day Range
$12.99
$26.01
52-Week Range
$10.40
$60.67
Volume
496,522 shs
Average Volume
418,815 shs
Market Capitalization
$968.41 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$38.60

BioLife Solutions MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
67.2% Upside
$38.00 Price Target
Short Interest
Bearish
6.44% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.37mentions of BioLife Solutions in the last 14 days
Based on 17 Articles This Week
Insider Trading
Selling Shares
$330,022 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.62) to ($0.18) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.03 out of 5 stars

Medical Sector

753rd out of 1,122 stocks

Electromedical Equipment Industry

16th out of 24 stocks

BLFS stock logo

About BioLife Solutions (NASDAQ:BLFS) Stock

BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services. It markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was incorporated in 1987 and is headquartered in Bothell, Washington.

BioLife Solutions Price Performance

Shares of NASDAQ:BLFS opened at $25.35 on Wednesday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 2.54 and a current ratio of 3.55. The business has a 50-day moving average of $17.27 and a two-hundred day moving average of $18.71. BioLife Solutions has a 12 month low of $10.40 and a 12 month high of $60.67.

Analyst Ratings Changes

Several research firms recently commented on BLFS. Maxim Group dropped their target price on BioLife Solutions from $60.00 to $30.00 in a research note on Thursday, May 12th. Oppenheimer upgraded BioLife Solutions from a "market perform" rating to an "outperform" rating in a research note on Monday, April 25th. Cowen dropped their target price on BioLife Solutions from $50.00 to $32.00 in a research note on Tuesday, May 10th. B. Riley dropped their price target on BioLife Solutions from $48.00 to $34.00 in a research note on Tuesday, May 17th. Finally, Cowen dropped their price target on BioLife Solutions to $29.00 in a research note on Monday. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $38.00.

Insider Transactions at BioLife Solutions

In other news, COO Greef Roderick De sold 9,158 shares of the company's stock in a transaction dated Tuesday, July 12th. The stock was sold at an average price of $15.79, for a total value of $144,604.82. Following the completion of the sale, the chief operating officer now owns 124,458 shares of the company's stock, valued at $1,965,191.82. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other news, COO Greef Roderick De sold 9,158 shares of the company's stock in a transaction dated Tuesday, July 12th. The stock was sold at an average price of $15.79, for a total value of $144,604.82. Following the completion of the sale, the chief operating officer now owns 124,458 shares of the company's stock, valued at $1,965,191.82. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CRO Marcus Schulz sold 4,600 shares of the company's stock in a transaction dated Wednesday, August 3rd. The stock was sold at an average price of $20.03, for a total value of $92,138.00. Following the completion of the sale, the executive now directly owns 36,218 shares of the company's stock, valued at approximately $725,446.54. The disclosure for this sale can be found here. Insiders sold 19,602 shares of company stock valued at $330,022 over the last quarter. Company insiders own 3.30% of the company's stock.

Receive BLFS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioLife Solutions and its competitors with MarketBeat's FREE daily newsletter.

BLFS Stock News Headlines

Tailor an Options Trading Strategy to Fit Your Needs
This guide will help you identify and execute an options trading strategy that fits your specific needs and risk profile. Take your trading to the next level with the Options Strategy Guide. pixel
BioLife Solutions (NASDAQ:BLFS) Trading 14.5% Higher
Tailor an Options Trading Strategy to Fit Your Needs
This guide will help you identify and execute an options trading strategy that fits your specific needs and risk profile. Take your trading to the next level with the Options Strategy Guide. pixel
BioLife Solutions (BLFS) Scheduled to Post Earnings on Tuesday
BioLife Solutions Inc. News
BioLife Solutions, Inc. (BLFS)
BioLife Solutions Tops Q1 EPS by 8c
See More Headlines
Receive BLFS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioLife Solutions and its competitors with MarketBeat's FREE daily newsletter.

BLFS Company Calendar

Last Earnings
11/11/2021
Today
8/17/2022
Next Earnings (Estimated)
11/10/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Electromedical equipment
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BLFS
Employees
432
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$38.00
High Stock Price Forecast
$65.00
Low Stock Price Forecast
$29.00
Forecasted Upside/Downside
+69.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-7,640,000.00
Pretax Margin
-71.64%

Debt

Sales & Book Value

Annual Sales
$119.16 million
Book Value
$9.68 per share

Miscellaneous

Free Float
41,199,000
Market Cap
$968.41 million
Optionable
Not Optionable
Beta
1.99














BLFS Stock - Frequently Asked Questions

Should I buy or sell BioLife Solutions stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioLife Solutions in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BLFS shares.
View BLFS analyst ratings
or view top-rated stocks.

What is BioLife Solutions' stock price forecast for 2022?

4 Wall Street analysts have issued twelve-month target prices for BioLife Solutions' stock. Their BLFS share price forecasts range from $29.00 to $65.00. On average, they anticipate the company's stock price to reach $38.00 in the next twelve months. This suggests a possible upside of 67.2% from the stock's current price.
View analysts price targets for BLFS
or view top-rated stocks among Wall Street analysts.

How have BLFS shares performed in 2022?

BioLife Solutions' stock was trading at $37.27 at the start of the year. Since then, BLFS shares have decreased by 39.0% and is now trading at $22.73.
View the best growth stocks for 2022 here
.

When is BioLife Solutions' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 10th 2022.
View our BLFS earnings forecast
.

How were BioLife Solutions' earnings last quarter?

BioLife Solutions, Inc. (NASDAQ:BLFS) issued its quarterly earnings data on Thursday, November, 11th. The medical equipment provider reported ($0.19) EPS for the quarter, missing analysts' consensus estimates of $0.02 by $0.21. The medical equipment provider earned $33.80 million during the quarter, compared to analysts' expectations of $31.65 million. BioLife Solutions had a negative trailing twelve-month return on equity of 7.54% and a negative net margin of 64.09%. During the same quarter last year, the firm earned ($0.02) earnings per share.

What guidance has BioLife Solutions issued on next quarter's earnings?

BioLife Solutions updated its FY 2022 earnings guidance on Tuesday, August, 16th. The company provided EPS guidance of for the period. The company issued revenue guidance of $160.00 million-$166.00 million, compared to the consensus revenue estimate of $163.00 million.

What is Mike Rice's approval rating as BioLife Solutions' CEO?

14 employees have rated BioLife Solutions Chief Executive Officer Mike Rice on Glassdoor.com. Mike Rice has an approval rating of 100% among the company's employees. This puts Mike Rice in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 89.0% of employees surveyed would recommend working at BioLife Solutions to a friend.

What other stocks do shareholders of BioLife Solutions own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioLife Solutions investors own include Micron Technology (MU), AbbVie (ABBV), Cara Therapeutics (CARA), Gilead Sciences (GILD), Pfizer (PFE), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), Twilio (TWLO) and Verastem (VSTM).

What is BioLife Solutions' stock symbol?

BioLife Solutions trades on the NASDAQ under the ticker symbol "BLFS."

Who are BioLife Solutions' major shareholders?

BioLife Solutions' stock is owned by many different institutional and retail investors. Top institutional shareholders include Millennium Management LLC (3.66%), Geneva Capital Management LLC (3.43%), State Street Corp (2.98%), Gagnon Securities LLC (1.35%), TimesSquare Capital Management LLC (1.15%) and Zweig DiMenna Associates LLC (1.10%). Insiders that own company stock include Aby J Mathew, Aby J Mathew, Andrew G Hinson, Andrew G Hinson, Casdin Partners Master Fund, L, Greef Roderick De, James Mathers, Johan Wedell-Wedellsborg, Joseph C Schick, Karen A Foster, Karen A Foster, Marcus Schulz, Michael Rice, Of The University Of C Regents, Raymond W Cohen, Sarah Aebersold, Thomas Girschweiler, Todd Berard, Troy Wichterman and Walter Villiger.
View institutional ownership trends
.

How do I buy shares of BioLife Solutions?

Shares of BLFS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BioLife Solutions' stock price today?

One share of BLFS stock can currently be purchased for approximately $22.73.

How much money does BioLife Solutions make?

BioLife Solutions (NASDAQ:BLFS) has a market capitalization of $968.41 million and generates $119.16 million in revenue each year. The medical equipment provider earns $-7,640,000.00 in net income (profit) each year or ($2.25) on an earnings per share basis.

How many employees does BioLife Solutions have?

The company employs 432 workers across the globe.

How can I contact BioLife Solutions?

BioLife Solutions' mailing address is 3303 MONTE VILLA PARKWAY SUITE 310, BOTHELL WA, 98021. The official website for the company is www.biolifesolutions.com. The medical equipment provider can be reached via phone at (425) 402-1400, via email at rdegreef@biolifesolutions.com, or via fax at 425-402-1433.

This page (NASDAQ:BLFS) was last updated on 8/18/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.